Madrigal Stock Skyrockets after Positive Topline Results from MAESTRO-NASH Clinical Trial
Madrigal Pharmaceuticals (MDGL) finished the trading session today 268.07% higher at $234.83 after unexpected positive topline results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of its drug Resmetirom
